Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr;16(3):795-796.
doi: 10.1007/s11739-021-02630-1. Epub 2021 Feb 3.

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply

Affiliations
Comment

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply

Amato De Monte et al. Intern Emerg Med. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CT has received funds for speaking at symposia organized on behalf of Pfizer, Novartis, Merck, Angelini, Zambon, Thermofischer, Biotest, Gilead, Hikma, Biomerieux and Astellas. All other authors declare that they have no conflict of interest.

Comment on

References

    1. Chirumbolo S, Pandolfi S, Valdenassi L, Bertossi D, Franzini M. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Comment Intern Emerg Med. 2020 doi: 10.1007/s11739-020-02542-6. - DOI - PMC - PubMed
    1. Tascini C, Sermann G, Pagotto A, Sozio E, De Carlo C, Giacinta A, Sbrana F, Ripoli A, Castaldo N, Merelli M, Cadeo B, Macor C, De Monte A. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Intern Emerg Med. 2020 doi: 10.1007/s11739-020-02542-6. - DOI - PMC - PubMed
    1. de Monte A, van der Zee H, Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J Altern Complement Med. 2005;11:363–367. doi: 10.1089/acm.2005.11.363. - DOI - PubMed
    1. Hernández A, Viñals M, Pablos A, Vilás F, Papadakos PJ, Wijeysundera D, Bergese SD, Vives M. Ozone therapy for patients with COVID-19 pneumonia: a preliminary report of a prospective case-control study. Int Immunopharmacol. 2020 doi: 10.1016/j.intimp.2020.107261. - DOI - PMC - PubMed
    1. Franzini M, Valdenassi L, Ricevuti G, Chirumbolo S, Depfenhart M, Bertossi D, Tirelli U. Oxygen-ozone (O2–O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. Int Immunopharmacol. 2020;88:106879. doi: 10.1016/j.intimp.2020.106879. - DOI - PMC - PubMed